Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Cytotoxic chemotherapies may expose the immune system to high levels of tumor antigens and expand the CD8(+) T-cell response to include weak or subdominant antigens. Here, we evaluated the in vivo CTL response to tumor antigens using a murine mesothelioma tumor cell line transfected with a neotumor antigen, ovalbumin, that contains a known hierarchy of epitopes for MHC class I molecules. We show that as tumors progress, effector CTLs are generated in vivo that focus on the dominant epitope SIINFEKL, although a weak response was seen to one (KVVRFDKL) subdominant epitope. These CTLs did not prevent tumor growth. Cisplatin treatment slowed tumor growth, slightly improved in vivo SIINFEKL presentation to T cells and reduced SIINFEKL-CTL activity. However, the CTL response to KVVRFDKL was amplified, and a response to another subdominant epitope, NAIVFKGL, was revealed. Similarly, gemcitabine cured most mice, slightly enhanced SIINFEKL presentation, reduced SIINFEKL-CTL activity yet drove a significant CTL response to NAIVFKGL, but not KVVRFDKL. These NAIVFKGL-specific CTLs secreted IFNγ and proliferated in response to in vitro NAIVFKGL stimulation. IL-2 treatment during chemotherapy refocused the response to SIINFEKL and simultaneously degraded the cisplatin-driven subdominant CTL response. These data show that chemotherapy reveals weaker tumor antigens to the immune system, a response that could be rationally targeted. Furthermore, while integrating IL-2 into the chemotherapy re…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cisplatin can broaden the spectrum of tumor antigens in vivo, thereby facilitating the cytotoxic T-cell response [39].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [39]
Citations
Cites
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
IMMUNODOMINANCE IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I–RESTRICTED T LYMPHOCYTE RESPONSES
Yewdell, J. W., & Bennink, J. R. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.51 · Cited by 944
Virus-Specific CD8+ T Cells in Primary and Secondary Influenza Pneumonia
Flynn, K. J., Belz, G. T., Altman, J. D., Ahmed, R., Woodland, D. L., & Doherty, P. C. (1998) · Immunity · doi:10.1016/s1074-7613(00)80573-7 · Cited by 674
Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading
Miller, S. D., Vanderlugt, C. L., Begolka, W. S., Pao, W., Yauch, R. L., Neville, K. L., Katz-Levy, Y., Carrizosa, A., & Kim, B. S. (1997) · Nature Medicine · doi:10.1038/nm1097-1133 · Cited by 565
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Self-citationDeterminant spreading and the dynamics of the autoimmune T-cell repertoire
Lehmann, P. V., Sercarz, E. E., Forsthuber, T., Dayan, C. M., & Gammon, G. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90163-f · Cited by 461
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Self-citationMartins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Disis, M. L., Grabstein, K. H., Sleath, P. R., & Cheever, M. A. (1999) · PubMed · Cited by 340
Chen, W., Antón, L. C., Bennink, J. R., & Yewdell, J. W. (2000) · Immunity · doi:10.1016/s1074-7613(00)80161-2 · Cited by 309
Butterfield, L. H., Ribas, A., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D. K., Wang, H.-J., Elashoff, R. M., McBride, W. H., Mukherji, B., et al. (2003) · PubMed · Cited by 255
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2002) · PubMed · Cited by 238
Self-citationChen, W., Khilko, S., Fecondo, J., Margulies, D. H., & McCluskey, J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1471 · Cited by 204
Immunogenic cell death modalities and their impact on cancer treatment
Kepp, O., Tesniere, A., Schlemmer, F., Michaud, M., Senovilla, L., Zitvogel, L., & Kroemer, G. (2009) · Apoptosis · doi:10.1007/s10495-008-0303-9 · Cited by 204
Jackaman, C., Bundell, C. S., Kinnear, B. F., Smith, A. M., Filion, P., van Hagen, D., Robinson, B. W. S., & Nelson, D. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5051 · Cited by 203
Self-citationFeltkamp, M. C. W., Vreugdenhil, G. R., Vierboom, M. P. M., Ras, E., van der Burg, S. H., Schegget, J. T., Melief, C. J. M., & Kast, W. M. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250935 · Cited by 166
Obeid, M., Panaretakis, T., Tesniere, A., Joza, N., Tufi, R., Apetoh, L., Ghiringhelli, F., Zitvogel, L., & Kroemer, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1622 · Cited by 161
Dong, Q., Louahed, J., Vink, A., Sullivan, C. D., Messler, C. J., Zhou, Y., Haczku, A., Huaux, F., Arras, M., Holroyd, K. J., et al. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199907)29:07<2130::aid-immu2130>3.0.co;2-s · Cited by 128
Immunogenic anti-cancer chemotherapy as an emerging concept
Haynes, N. M., der Most, R. G. V., Lake, R., & Smyth, M. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.008 · Cited by 114
Determinant spreading and tumor responses after peptide-based cancer immunotherapy
Ribas, A., Timmerman, J. M., Butterfield, L. H., & Economou, J. S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00029-7 · Cited by 114
Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif
Lipford, G. B., Hoffman, M., Wagner, H., & Heeg, K. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.4.1212 · Cited by 108
CD1high B cells: a population of mixed origin
Makowska, A., Faizunnessa, N. N., Anderson, P. O., Midtvedt, T., & Cardell, S. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199910)29:10<3254::aid-immu3254>3.0.co;2-0 · Cited by 86
Anti-CTLA-4 Antibody Treatment Triggers Determinant Spreading and Enhances Murine Myasthenia Gravis
Wang, H., Shi, F., Li, H., Chambers, B. J., Link, H., & Ljunggren, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.6430 · Cited by 76
Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading
Ranieri, E., Kierstead, L. S., Zarour, H. M., Kirkwood, J. M., Lotze, M. T., Whiteside, T. L., & Storkus, W. J. (2000) · Immunological Investigations · doi:10.3109/08820130009062294 · Cited by 68
Nelson, D. J., Mukherjee, S., Bundell, C., Fisher, S., van Hagen, D., & Robinson, B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5557 · Cited by 65
Self-citationDeliberately provoking local inflammation drives tumors to become their own protective vaccine site
Jackaman, C., Lew, A. M., Zhan, Y., Allan, J. E., Koloska, B., Graham, P. T., Robinson, B. W. S., & Nelson, D. J. (2008) · International Immunology · doi:10.1093/intimm/dxn104 · Cited by 65
Self-citationCD40‐activated B cells contribute to mesothelioma tumor regression
Jackaman, C., Cornwall, S. M. J., Graham, P. T., & Nelson, D. J. (2010) · Immunology and Cell Biology · doi:10.1038/icb.2010.88 · Cited by 63
Self-citationReynolds, P., Gordon, T. P., Purcell, A. W., Jackson, D. C., & McCluskey, J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.5.1857 · Cited by 63
Nelson, D. J., Bundell, C. S., & Robinson, B. W. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6123 · Cited by 63
Self-citationButtiglieri, S., Galetto, A., Forno, S., De Andrea, M., & Matera, L. (2003) · International Journal of Cancer · doi:10.1002/ijc.11243 · Cited by 59
Markiewicz, M. A., Fallarino, F., Ashikari, A. Y., & Gajewski, T. F. (2001) · International Immunology · doi:10.1093/intimm/13.5.625 · Cited by 50
Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells
Larsson, M., Wilkens, D. T., Fonteneau, J., Beadle, T. J., Merritt, M. J., Kost, R. G., Haslett, P. A. J., Cu‐Uvin, S., Bhardwaj, N., Nixon, D. F., et al. (2002) · AIDS · doi:10.1097/00002030-200201250-00005 · Cited by 46
Theiler's Virus‐Mediated Autoimmunity
Tompkins, S. M., Fuller, K. G., & Miller, S. D. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02944.x · Cited by 38
T Cell Therapy for Nasopharyngeal Carcinoma
Basso, S., Zecca, M., Merli, P., Gurrado, A., Secondino, S., Quartuccio, G., Guido, I., Guerini, P., Ottonello, G., Zavras, N., et al. (2011) · Journal of Cancer · doi:10.7150/jca.2.341 · Cited by 33
Epitope spreading occurs in active but not passive EAE induced by myelin basic protein
Voskuhl, R. R., Farris, R. W., Nagasato, K., McFarland, H. F., & Dubois-Dalcq, M. E. (1996) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00054-9 · Cited by 30
Newmaster, R. S., Mylin, L. M., Fu, T., & Tevethia, S. S. (1998) · Virology · doi:10.1006/viro.1998.9148 · Cited by 29
Subklewe, M. S., Sebelin, K., Block, A., Meier, A., Roukens, A. H. E., Paludan, C., Fonteneau, J., Steinman, R. M., & Münz, C. (2005) · Human Immunology · doi:10.1016/j.humimm.2005.07.003 · Cited by 26
Mok, H., Lee, S., Wright, D. W., & Crowe, J. E. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.07.012 · Cited by 25
Harnessing self-reactivity in cancer immunotherapy
Schoenberger, S. P., & Sercarz, E. E. (1996) · Seminars in Immunology · doi:10.1006/smim.1996.0039 · Cited by 23
Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki, A., Weidt, G., Blachère, N. E., Lefrançois, L., & Srivastava, P. K. (2002) · PubMed · Cited by 22
The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy.
Monden, N., Abe, S., Hishikawa, Y., Yoshimura, H., Kinugasa, S., Dhar, D. K., Tachibana, M., & Nagasue, N. (1999) · PubMed · Cited by 18
Sharma, A. K., Allam, R., Ray, R., & Rajeswari, M. R. (2009) · DNA and Cell Biology · doi:10.1089/dna.2009.0851 · Cited by 16
Vallbracht, S., Jessen, B., Mrusek, S., Enders, A., Collins, P. L., Ehl, S. R., & Krempl, C. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.12.8264 · Cited by 16
Melief, C. J. M., & Kast, W. M. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514672.ch7 · Cited by 15
Cheuk, E., & Chamberlain, J. W. (2005) · Cellular Immunology · doi:10.1016/j.cellimm.2005.06.004 · Cited by 13
Research works printed but not linked: 4
- el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29:3295–3301 · DOI · Paper page
- Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J (1994) Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 180:1471–1483 · DOI · Paper page
- Lipford GB, Hoffman M, Wagner H, Heeg K (1993) Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol 150:1212–1222 · DOI
- Grufman P, Wolpert EZ, Sandberg JK, Karre K (1999) T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur J Immunol 29:2197–2204 · doi:10.1002/(sici)1521-4141(199907)29:07<2197::aid-immu2197>3.0.co;2-b
Cited by
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 557
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
Romani, A. M. P. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115323 · Cited by 383
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Metadata
- Authors
- Jackaman, C., Majewski, D., Fox, S. A., Nowak, A. K., & Nelson, D. J.
- Affiliations
- Curtin University (AU)
- The University of Western Australia (AU)
- Corresponding author
- Nelson, Delia J.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2012-06-20
- Volume
- 61
- Issue
- 12
- Pages
- 2343-2356
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029427
- OpenAlex
- W2078500268
- Cited by
- 105
- References
- 47
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 9 · 2022: 16 · 2021: 12 · 2020: 9 · 2019: 10 · 2018: 7 · 2017: 6 · 2016: 6 · 2015: 1 · 2014: 4 · 2013: 5
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- University of Queensland
- Curtin University of Technology
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- chemotherapy, tumor antigens, CD8+ cytotoxic T lymphocytes, subdominant epitopes, mesothelioma, ovalbumin, SIINFEKL, cisplatin, gemcitabine, interleukin-2, interferon-gamma, tumor immunology, cancer immunotherapy
- MeSH terms
- Gemcitabine, Animals, Epitopes, Antigens, Neoplasm, Antineoplastic Agents, Cisplatin, Cytotoxicity, Immunologic, Deoxycytidine, Female, Interferon-gamma, Interleukin-2, Mesothelioma, Mice, Inbred C57BL, Ovalbumin, T-Lymphocytes, Cytotoxic, Transfection, Histocompatibility Antigens Class I, Antigen Presentation, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.